187 related articles for article (PubMed ID: 9101355)
61. Influence of the route of administration and the chemical form (MnCl2, MnO2) on the absorption and cerebral distribution of manganese in rats.
Roels H; Meiers G; Delos M; Ortega I; Lauwerys R; Buchet JP; Lison D
Arch Toxicol; 1997; 71(4):223-30. PubMed ID: 9101038
[TBL] [Abstract][Full Text] [Related]
62. Dephosphorylation of MnDPDP and related compounds by acid and alkaline phosphatase.
Toft KG; Myrset AH; Skotland T
J Pharm Biomed Anal; 2001 Jun; 25(3-4):613-8. PubMed ID: 11377042
[TBL] [Abstract][Full Text] [Related]
63. Biodistribution and in vivo stability of manganese dipyridoxyl diphosphate in relation to imaging efficacy.
Grant D; Zech K; Holtz E
Invest Radiol; 1994 Jun; 29 Suppl 2():S249-50. PubMed ID: 7928247
[No Abstract] [Full Text] [Related]
64. Mangafodipir trisodium injection (Mn-DPDP). A contrast agent for abdominal MR imaging.
Rofsky NM; Earls JP
Magn Reson Imaging Clin N Am; 1996 Feb; 4(1):73-85. PubMed ID: 8673718
[TBL] [Abstract][Full Text] [Related]
65. Preclinical evaluation of MnDPDP: new paramagnetic hepatobiliary contrast agent for MR imaging.
Elizondo G; Fretz CJ; Stark DD; Rocklage SM; Quay SC; Worah D; Tsang YM; Chen MC; Ferrucci JT
Radiology; 1991 Jan; 178(1):73-8. PubMed ID: 1898538
[TBL] [Abstract][Full Text] [Related]
66. Pancreatic enhancement after low-dose infusion of Mn-DPDP.
Gehl HB; Vorwerk D; Klose KC; Günther RW
Radiology; 1991 Aug; 180(2):337-9. PubMed ID: 1906189
[TBL] [Abstract][Full Text] [Related]
67. Glutamate/aspartate transporter (GLAST), taurine transporter and metallothionein mRNA levels are differentially altered in astrocytes exposed to manganese chloride, manganese phosphate or manganese sulfate.
Erikson KM; Suber RL; Aschner M
Neurotoxicology; 2002 Sep; 23(3):281-8. PubMed ID: 12387356
[TBL] [Abstract][Full Text] [Related]
68. MnDPDP as a negative hepatic contrast agent: evaluation of STIR imaging compared with T1-weighted SE and GE techniques.
Halavaara JT; Lamminen AE
J Comput Assist Tomogr; 1997; 21(1):94-9. PubMed ID: 9022776
[TBL] [Abstract][Full Text] [Related]
69. Mn-DPDP-enhanced MR imaging of malignant liver lesions: efficacy and safety in 20 patients.
Aicher KP; Laniado M; Kopp AF; Grönewäller E; Duda SH; Claussen CD
J Magn Reson Imaging; 1993; 3(5):731-7. PubMed ID: 8400558
[TBL] [Abstract][Full Text] [Related]
70. Metabolism of mangafodipir trisodium (MnDPDP), a new contrast medium for magnetic resonance imaging, in beagle dogs.
Toft KG; Hustvedt SO; Grant D; Friisk GA; Skotland T
Eur J Drug Metab Pharmacokinet; 1997; 22(1):65-72. PubMed ID: 9179562
[TBL] [Abstract][Full Text] [Related]
71. Occlusive and reperfused myocardial infarcts: differentiation with Mn-DPDP--enhanced MR imaging.
Saeed M; Wagner S; Wendland MF; Derugin N; Finkbeiner WE; Higgins CB
Radiology; 1989 Jul; 172(1):59-64. PubMed ID: 2500678
[TBL] [Abstract][Full Text] [Related]
72. A new opportunity for MEMRI.
Cloyd R; Vandsburger M; Abisambra JF
Aging (Albany NY); 2017 Aug; 9(8):1855-1856. PubMed ID: 28854148
[No Abstract] [Full Text] [Related]
73. Clinical implications of studies with MnDPDP in animal models of hepatic abnormalities.
Ni Y; Marchal G
Acta Radiol; 1997 Jul; 38(4 Pt 2):724-31. PubMed ID: 9245968
[TBL] [Abstract][Full Text] [Related]
74. Changes in ECG and enzyme activity in rat heart after myocardial infarction: effect of TPP and MnCl2.
Tylicki A; Czerniecki J; Godlewska A; Kieliszek M; Zebrowski T; Bielawski T; Wojcik B
J Physiol Biochem; 2008 Jun; 64(2):93-101. PubMed ID: 19043979
[TBL] [Abstract][Full Text] [Related]
75. Technical report: lymph node enhancement at MRI with MnDPDP in primary hepatic carcinoma.
Burkill GJ; Mannion EM; Healy JC
Clin Radiol; 2001 Jan; 56(1):67-71. PubMed ID: 11162701
[TBL] [Abstract][Full Text] [Related]
76. Functioning acinar cell pancreatic carcinoma: diagnosis on mangafodipir trisodium (Mn-DPDP)-enhanced MRI.
Sahani D; Prasad SR; Maher M; Warshaw AL; Hahn PF; Saini S
J Comput Assist Tomogr; 2002; 26(1):126-8. PubMed ID: 11801915
[TBL] [Abstract][Full Text] [Related]
77. Manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate): clinical experience with a new contrast agent.
Rofsky NM; Weinreb JC
Magn Reson Q; 1992 Sep; 8(3):156-68. PubMed ID: 1390058
[TBL] [Abstract][Full Text] [Related]
78. MR cholangiography with manganese dipyridoxyl diphosphate in the evaluation of biliary-enteric anastomoses: preliminary experience.
Hottat N; Winant C; Metens T; Bourgeois N; Devière J; Matos C
AJR Am J Roentgenol; 2005 May; 184(5):1556-62. PubMed ID: 15855115
[TBL] [Abstract][Full Text] [Related]
79. Detection of hepatic malignancies using Mn-DPDP (manganese dipyridoxal diphosphate) hepatobiliary MRI contrast agent.
Young SW; Bradley B; Muller HH; Rubin DL
Magn Reson Imaging; 1990; 8(3):267-76. PubMed ID: 2114511
[TBL] [Abstract][Full Text] [Related]
80. MR imaging assessment of experimental hepatic dysfunction with Mn-DPDP.
Coley BD; Mattrey RF; Baker KG; Peterson T; Burgan AR
J Magn Reson Imaging; 1995; 5(1):11-6. PubMed ID: 7696800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
